Last reviewed · How we verify
liposomal preparation of anthralin
liposomal preparation of anthralin is a Small molecule drug developed by Assiut University. It is currently FDA-approved.
Liposomal preparation of anthralin, developed by Assiut University, is currently marketed but lacks detailed revenue figures and primary indication data. The key strength lies in its unique liposomal formulation, which may offer improved efficacy and safety profiles compared to conventional anthralin treatments. However, the primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | liposomal preparation of anthralin |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- liposomal preparation of anthralin CI brief — competitive landscape report
- liposomal preparation of anthralin updates RSS · CI watch RSS
- Assiut University portfolio CI